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provides an alternative to the transvenous ICD for the prevention of
sudden cardiac death, but has not been well studied in the most
commonly treated transvenous ICD patient population, namely,
primary prevention (PP) patients with left ventricular dysfunction.
OBJECTIVE The analyses in the present study were designed to
compare clinical outcomes for PP patients with and without a
reduced ejection fraction (EF) and secondary prevention (SP)
patients implanted with the S-ICD.
METHODS All patients 18 years and older from the S-ICD IDE study
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1016/j.hrthm.2016.11.0252013, were included (n ¼ 856; mean follow-up duration 644 days).
Outcomes were evaluated in 2 analyses: (1) comparing all PP
patients (n ¼ 603, 70.4%) with all SP patients (n ¼ 253, 29.6%)
and (2) comparing all PP patients with an EF ≤35% (n ¼ 379) with
those with an EF 435% (n ¼ 149, 17.4%).
RESULTS No differences were observed in mortality, complica-
tions, inappropriate therapy, or ability to convert ventricular
tachyarrhythmias between SP and PP patients. However, SP
patients had a higher incidence of appropriate therapy than did
PP patients (11.9% vs 5.0%; P ¼ .0004). In the PP subanalysis, the
cohort with an EF ≤35% had signiﬁcantly older patients with more
comorbidities and higher mortality (3.0% annually vs 0.0%).
Despite these differences, device-related complications, conversion
efﬁcacy, and incidence of inappropriate shock therapies were not
signiﬁcantly different between PP subgroups.
CONCLUSION The S-ICD performs well in protecting patients with
either PP or SP implant indications from sudden cardiac death.
Within PP patients, device performance was independent of EF.
KEYWORDS Subcutaneous ICD; Primary prevention; Secondary
prevention; Ejection fraction; Appropriate shock
(Heart Rhythm 2016;0:1–9) I 2016 The Authors. Published by
Elsevier Inc. on behalf of Heart Rhythm Society. All rights reserved.Introduction
The beneﬁt of implantable deﬁbrillator (ICD) therapy in
reducing arrhythmic death in patients with either a secondarybehalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/10.
Heart Rhythm, Vol 0, No 0, ] 20162prevention (SP)1,2 or a primary prevention (PP) indication3,4
has been established through a number of studies over the
past 2 decades. As these studies have resulted in an increased
number of patients receiving a transvenous ICD (TV-ICD),
the incidence of device- and lead-related complications
requiring reoperation or explantation has also increased
concomitantly.5,6
The subcutaneous implantable deﬁbrillator (S-ICD) was
developed as an alternative to the TV-ICD, without the need
to implant transvenous or epicardial leads. The safety and
effectiveness of the S-ICD has been established,7,8 and the
largest S-ICD studies include a wide variety of ICD-
indicated patients.9 The S-ICD is often selected for younger
patients with inherited diseases and normal ventricular
function,10 yet patients with the more common indication
of a reduced left ventricular (LV) ejection fraction (EF)
remain the largest major subgroup implanted. We sought to
understand the device performance and patient outcomes in
patients with a PP indication, and speciﬁcally those with a
reduced EF. We retrospectively evaluated the long-term
clinical outcomes of patients implanted with the S-ICD for
both primary and secondary indications. A second analysis
was performed to compare outcomes for PP patients with an
EF cutoff of ≤35% (“PP EF ≤35%”) with those for PP
patients with an EF435% (“PP EF 435%”).Methods
Patient population
The patients included in the analysis were those implanted as
part of the pivotal S-ICD System Clinical Investigation
(“IDE study”) and the initial cohort of the EFFORTLESS
S-ICD Registry (“EFFORTLESS Registry”) as previously
described.11 In brief, the IDE study was designed to
demonstrate the safety and efﬁcacy of the S-ICD system
for Food and Drug Administration approval while the
EFFORTLESS Registry is an ongoing standard-of-care
postmarket evaluation of long-term clinical outcomes in
1000 patients commercially implanted with the S-ICD in
countries outside the United States. For the IDE study, the
data presented reﬂect information from all implanted patients
(implanted between January 27, 2010, and May 20, 2011),
while for the ongoing EFFORTLESS Registry, the data
reﬂect information available as of November 18, 2013 (ﬁrst
implantation on August 20, 2009). Ethical approval was
obtained in all centers for the purpose of each study, and all
patients provided informed consent according to national and
institutional regulations.
For the present analysis, the initial pooled data set consists
of 889 enrolled patients: 308 from the IDE study, 568 from
the EFFORTLESS Registry, and 13 patients common to the
2 studies. The analysis included patients from 58 clinical
centers in 8 countries. Twenty-nine patients were subse-
quently excluded from the analysis because they were
younger than 18 years at the time of implantation, and an
additional 4 patients were excluded because of insufﬁcient
baseline data to characterize the indication for implantation.The remaining 856 patients are included in the analysis of SP
and PP patients for all-cause mortality and device- and
procedure-related complications. Only patients successfully
implanted with the S-ICD system (853) are included in the
analysis of shock therapy (appropriate and inappropriate).
The analysis of PP patients by EF level included all PP
patients with sufﬁcient EF data. EF measurements were
recorded as available for patients in the IDE study and
EFFORTLESS Registry. Device programming was left to
the discretion of the implanting physician in both studies.
Statistical and data analysis
All outcomes were evaluated through the latest available
follow-up. Two separate analyses were completed. First,
clinical outcomes for all patients implanted for SP were
compared with patients implanted for PP. Second, a sub-
sequent analysis further subdivided the PP patients on the
basis of EF into PP EF 435% or PP EF ≤35%. The
appropriateness of pooling study data, event deﬁnitions, and
event adjudications have been previously described.8,10
Baseline demographic and clinical characteristics, includ-
ing medical history, risk factors, comorbidities, and New
York Heart Association functional class for heart failure, are
presented as available. Continuous variables are summarized
as means ± SDs or as medians and ranges, where appro-
priate. Continuous data were compared using the Student t
test. Categorical variables are summarized as frequencies and
percentages and compared using the χ2 test. Freedom from
complications, mortality, and appropriate shock and inap-
propriate shock rates are analyzed using the Kaplan-Meier
method. All statistical analyses were performed using SAS
Enterprise Guide, version 5.1 (SAS 9.3, SAS Institute Inc.
NC USA).
Results
Of the 856 patients in the primary analysis cohort, 29.6%
were SP patients (n = 253) and 70.4% were PP patients (n =
603). Of the 603 PP patients, 379 had an EF ≤35% (62.9%),
149 had an EF 435% (24.7%), and 75 (12.4%) lacked
sufﬁcient data to determine baseline LVEF. Missing LVEF
values were observed primarily in the EFFORTLESS
Registry, predominantly in patients with etiologies that are
not characterized by low EF. The mean follow-up duration
for all patients was 644 days, with a range of 2–1542 days
(median 633 days). There were no signiﬁcant differences in
follow-up duration between any of the groups evaluated
(663, 636, 621, and 658 days for SP, PP, PP EF ≤35%, and
PP EF 435%, respectively).
Baseline demographic characteristics
Patient characteristics and baseline demographic character-
istics are summarized in Tables 1 and 2. In general, SP
patients had a lower incidence of comorbidities than did PP
patients (Table 1). The mean LVEF was signiﬁcantly higher
in SP patients (48%) than in PP patients (36%) (Po .0001).
PP patients had a signiﬁcantly higher incidence of congestive
Table 1 Baseline demographic and clinical characteristics of secondary prevention and primary prevention patients
Demographic Statistic/Category Secondary Prevention Patients Primary Prevention Patients P-Value
Gender Male 180 (71.1) 442 (73.3) 0.5188
Medical History NYHA Classiﬁcation II-IV (n, %) 49 (19.4) 278 (46.3) o.0001
Atrial Fibrillation 47 (18.7) 94 (15.6) 0.2802
COPD 12 (4.8) 44 (7.3) 0.1669
Diabetes 24 (9.5) 132 (22.0) o.0001
Hypertension 81 (32.1) 250 (41.7) 0.0092
Myocardial Infarction 70 (27.8) 232 (38.7) 0.0024
Stroke 9 (3.6) 36 (6.0) 0.1481
Valve Disease 35 (13.9) 79 (13.2) 0.7775
Ablation 17 (6.7) 23 (3.8) 0.0666
CABG 32 (12.7) 69 (11.5) 0.6214
Percutaneous Revascularization 45 (17.9) 150 (25.0) 0.0242
Valve Surgery 25 (9.9) 27 (4.5) 0.0026
Prior Pacemaker 7 (2.8) 15 (2.5) 0.8127
Prior Deﬁbrillator 70 (27.8) 49 (8.2) o.0001
Explant Due to Infection 43 (17.1) 33 (5.5) o.0001
Explant Due to Lead Failure 21 (8.3) 9 (1.5) o.0001
Values are presented as mean ± SD, mean ± SD (range), or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; NYHA ¼ New York Heart Association.
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diabetes, hypertension, and prior myocardial infarction than
did SP patients and were more likely to have previously
undergone a percutaneous revascularization procedure, but
not coronary artery bypass. Nearly 30% of SP patients had
previously undergone an implantation of a TV-ICD, the
majority of which (61.4%) had been explanted because of
infection. This compares to only 8.2% of PP patients, who
had received a TV-ICD. Primary underlying disease can be
seen in Figure 1A: 41% of the PP patients had ischemic
cardiomyopathy and 28% nonischemic cardiomyopathy as
compared to the SP population composed of 33% ischemic
and 12% nonischemic cardiomyopathy patients.
Within the PP group, there were signiﬁcant differences
between subgroups with respect to medical history,Table 2 Baseline demographic and clinical characteristics of primary pr
≥35% (PP EF435%)
Demographic Statistic/Category Primary Prevention
Gender Male 299 (78.9)
Medical History NYHA Classiﬁcation II-IV (n, %) 260 (68.8)
Atrial Fibrillation 81 (21.4)
COPD 36 (9.5)
Diabetes 117 (31.0)
Hypertension 216 (57.3)
Myocardial Infarction 218 (57.8)
Stroke 31 (8.2)
Valve Disease 65 (17.2)
Ablation 13 (3.4)
CABG 67 (17.8)
Percutaneous Revascularization 142 (37.6)
Value Surgery 21 (5.6)
Prior Pacemaker 9 (2.4)
Prior Deﬁbrillator 26 (6.9)
Explant Due to Infection 21 (5.6)
Explant Due to Lead Failure 2 (0.5)
Values are presented as mean ± SD, mean ± SD (range), or percentage.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; COPD ¼ chroncomorbidities, and underlying disease (Table 2). Patients in
the PP EF ≤35% cohort were the oldest group (mean age 57
years) and were signiﬁcantly older than those in the PP EF
435% cohort (mean age 40 years). The mean LVEF in the
PP EF ≤35% group measured 26% ± 6% vs 60% ± 10% in
the PP EF 435% group, suggesting overall a relatively
preserved EF cohort. Patients with an EF ≤35% had more
overall comorbidities. For example, 68.8% had a history of
congestive heart failure vs 9.4% of patients with an EF
435% (Po .0001). Likewise, the incidence of a history of
diabetes, hypertension, and myocardial infarction was
31.0%, 57.3%, and 57.8% for those in the PP EF ≤35%
cohort vs 7.4%, 17.4%, and 7.4%, respectively, for those
with an EF 435%. Among patients whose EF was435%,
the majority had either hypertrophic cardiomyopathy (40%)evention patients with an ejection fraction ≤35% (PP EF ≤35%) and
Low EF Patients Primary Prevention High EF Patients P-Value
98 (65.3) 0.0012
14 (9.4) o.0001
9 (6.0) o.0001
6 (4.0) 0.0353
11 (7.4) o.0001
26 (17.4) o.0001
11 (7.4) o.0001
3 (2.0) 0.0091
9 (6.0) 0.0009
7 (4.7) 0.4995
2 (1.3) o.0001
6 (4.0) o.0001
4 (2.7) 0.1610
2 (1.3) 0.4526
16 (10.7) 0.1406
9 (6.0) 0.8288
4 (2.7) 0.0357
ic obstructive pulmonary disease; NYHA ¼ New York Heart Association.
Figure 1 A:Differences in clinical etiology of secondary prevention and primary prevention patients. B:Differences in clinical etiology of primary prevention
patients with an ejection fraction ≤35% (PP EF ≤35%) and with an ejection fraction435% (PP EF ≥35%).
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ischemic disease, whereas those with a reduced EF had
mostly ischemic (62%) or nonischemic (34%) cardiomyop-
athy (Figure 1B).Procedure- and device-related complications
Despite the differences in clinical characteristics, comor-
bidities, and underlying substrate, the incidence of
device- and procedure-related complications was not
signiﬁcantly different for any of the groups, and the risk
of clinical complications was generally low. The major-
ity of clinical complications were documented within the
ﬁrst 90 days of the procedure in all groups. The most
commonly reported clinical complication was due to
device system infection (n ¼ 17 total events in 15
patients [1.8%]).
A total of 25 of 253 SP patients experienced a clinical
complication during follow-up (9.9%) vs 57 of 603 (9.4%)
PP patients (see Kaplan-Meier curves for freedom from
complications in Figure 2). After 3 years of follow-up, the
complication-free rate was 88.5% in SP patients vs 88.7% inA
Figure 2 A: Kaplan-Meier curves demonstrating freedom from device- and p
subcutaneous implantable deﬁbrillator patients. B: Kaplan-Meier curves demons
primary prevention patients with an ejection fraction ≤35% (PP EF ≤35%) and wPP patients (0.77; Figure 2A). PP EF ≤35% and PP EF
435% cohorts were also similar, with 3-year complication-
free rates of 87.8% and 91.6%, respectively (P ¼ .76;
Figure 2B).
All-cause mortality
There was no signiﬁcant difference in mortality between the
2 groups (Figure 3A). There were 26 total deaths (3.1%)
documented over the duration of follow-up, with a rate of
2.3% (n ¼ 6) in the SP group vs 3.3% (n ¼ 20) in the PP
group. There was a signiﬁcant difference in mortality risk
within the PP group; all 19 deaths occurred in the PP EF
≤35% cohort of patients (5.0% total mortality). The overall
risk of death was also highest (3% annually) within this
cohort compared to all others (Figure 3B). Only 1 death is
reported to be arrhythmic, after a storm event, in a Lofﬂer
syndrome patient implanted for SP.8,9
Delivery of appropriate therapy
Device programming did not differ signiﬁcantly between
SP and PP patients with respect to the use of theB
rocedure-related complications between primary and secondary prevention
trating freedom from device- and procedure-related complications between
ith an ejection fraction 435% (PP EF435%).
BA
Figure 3 A: Kaplan-Meier curves demonstrating freedom from mortality between primary and secondary prevention subcutaneous implantable deﬁbrillator
patients. B:Kaplan-Meier curves demonstrating freedom from mortality between primary prevention patients with an ejection fraction ≤35% (PP EF ≤35%) and
with an ejection fraction435% (PP EF435%).
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grammed cutoff rates. However, far fewer devices were
programmed with a shock zone higher than 220 beats/min
(30.6%) in the PP EF ≤35% cohort than in the PP
EF 435% cohort (56% for 4220 beats/min). Also, a
higher proportion of devices in the PP EF ≤35% cohort
had cutoff rates programmed lower for both shock and
conditional zones than in the PP EF435% cohort (30.6%
vs 18.6% for o220 beats/min and 77.5% vs 62.1% for
o200 beats/min, respectively) (see Online Supplement
Table 1).
There were no differences between any of the groups in
the ability of the S-ICD to convert an induced ventricular
arrhythmia (ventricular tachycardia/ventricular ﬁbrillation
[VT/VF]) at the time of implantation. Conversion success
at 80 J was achieved in 98%–99% in all groups. Ninety-
ﬁve percent of SP patients vs 94% of PP patients had at
least 1 successful shock conversion at ≤65 J at the time of
implantation. There was also no difference in conversion
rate at ≤65 J within the 2 PP groups (94% for both EF
cohorts). The overall conversion efﬁcacy of the S-ICD for
spontaneous episodes VT/VF did not differ in the cohorts.
All (100%) discrete (deﬁned as episodes not part of a
storm event) spontaneous VT/VF arrhythmias were suc-
cessfully converted to sinus rhythm, with ~90% convert-
ing on the ﬁrst shock in both SP and PP patients (42 of 47
[89%] and 55 of 61 [90%], respectively). More details by
type of arrhythmia are provided in Online Supplement
Table 2. Only a single event of polymorphic ventricular
tachycardia/VT in each group failed to convert within the
deﬁned episode; one of these terminated beyond the time
limit of electrogram recording, while the other was
prematurely declared by the device as having terminated.
The device then immediately redetected and terminated
the episode.Incidence of treated and untreated VT/VF
All rhythms meeting device-deﬁned detection criteria for
VT/VF that were logged in the device were included in the
analysis of treated (appropriate therapy) vs untreated (self-
terminating) episodes for the respective patient cohorts.
There were signiﬁcant differences in the need for appropriate
therapy between the cohorts. The freedom from any appro-
priate VT/VF therapy was 84.2% in the SP group and 92.1%
in the PP group (Kaplan-Meier estimate over 3 years; P ¼
.0001; Figure 4A). In the PP subanalysis, freedom from
appropriate therapy was 88.4% in the PP EF ≤35% cohort vs
96.2% in the PP EF 435% cohort (Kaplan-Meier estimate
over 3 years; P ¼ .0724; Figure 4B).
In PP patients, almost half of the VT/VF episodes recorded
(48%) spontaneously terminated without the need for treatment,
while this proportion was lower in the SP group (31%). In SP
patients, VT/VF episodes were recorded in 16.3% of patients;
12.3% of patients received at least 1 appropriate therapy, 9.1%
experienced at least 1 self-terminating VT/VF episode, and
5.2% had both types of episodes. In contrast, only 10.1% of PP
patients had a VT/VF episode; 4.9% received at least 1
appropriate therapy, 7.5% had at least 1 self-terminating VT/
VF episode, and 2.3% had both types of episodes. Within the
PP group, both EF cohorts had a proportionately high rate of
patients experiencing spontaneous episodes of VT/VF that self-
terminated. In PP EF ≤35% patients, 6.4% received at least 1
appropriate therapy and 9.8% had at least 1 self-terminating
VT/VF episode as compared with 2.1% and 2.7%, respectively,
in PP EF435% patients (Figure 5).Incidence of inappropriate therapy
In contrast to the need for appropriate therapy, there was no
relationship between the incidence of inappropriate therapy
and SP or PP indication (Figure 6A). There was also no
A B
Figure 4 A: Kaplan-Meier curves demonstrating freedom from appropriate shock therapy between primary and secondary prevention subcutaneous
implantable deﬁbrillator patients. B: Kaplan-Meier curves demonstrating freedom from appropriate shock between primary prevention patients with an ejection
fraction ≤35% (PP EF ≤35%) and with an ejection fraction435% (PP EF435%).
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cohort (Figure 6B). Overall, 12.3% of SP patients received at
least 1 inappropriate shock over the duration of follow-up
compared with 10.2% of PP patients. The groups were
similar regardless of single- or dual-zone programming, as
the incidence of inappropriate therapy occurring with single-
zone programming (SP 18.0%; PP 18.0%; P ¼ 1.00) was
reduced in both groups by the presence of a second zone (SP
10.8%; PP 8.2%;P¼ .27). There was no signiﬁcant difference in
the incidence of inappropriate therapy between the 2 PP EF
cohorts (10.1% for PP EF ≤35% vs 11.6% for PP EF435%),
nor in the respective patient subsets with devices programmed
with dual zones (8.2% and 7.9%, respectively).Discussion
Overview
The S-ICD has emerged as a viable alternative to the TV-
ICD in varied patient populations.7–10 In addition, the S-ICDFigure 5 Incidence of patients experiencing treated ventricular tachycar-
dia/ventricular ﬁbrillation (VT/VF) episodes, self-terminating VT/VF epi-
sodes, or both types of episodes in secondary prevention patients, primary
prevention patients, primary prevention patients with an ejection fraction
≤35% (PP EF ≤35%), and primary prevention patients with an ejection
fraction435% (PP EF435%).may provide beneﬁts to speciﬁc patient groups such as
younger patients or TV-ICD patients requiring reimplanta-
tion after infection.11,12 Whether the S-ICD performs com-
parably to the TV-ICD in the population traditionally
referred for a PP indication remains to be determined. The
population selected for S-ICD implantation to date has been
younger, with a lower incidence of ischemic heart disease
and a lower overall cardiovascular risk than does the tradi-
tional TV-ICD population. In the present analysis, the PP EF
≤35% cohort better resembles the patients included in
historical TV-ICD trials, with a mean age of 60 years, a
mean EF of 26%, and a higher incidence of cardiac
comorbidities. This analysis demonstrates consistent
device-related outcomes, including procedural complica-
tions, shock efﬁcacy, and frequency of inappropriate shock
across all the groups evaluated. We did observe differences
in rates of VT/VF and overall mortality, likely related to age
and underlying etiology.
Device- and procedure-related outcomes
Despite the signiﬁcant demographic differences observed
between the SP and PP patient populations (and within the PP
population), there were no differences in complication rates
between any of the evaluated cohorts. While SP patients had a
prior TV-ICD explanted for reasons of infection 3 times more
often than PP patients, we saw no difference in the proportion of
patients that developed a postimplantation infection between the
2 groups. The consistency of complication rates between the 2
PP EF cohorts is also remarkable, considering that long-term
complication rates in TV-ICD studies are generally higher in
younger patients as well as in those patients with a lower EF.13–16
The low rates observed in the younger PP EF 435% cohort
provide support for S-ICD use in these patients.
The ability of the S-ICD to convert induced and sponta-
neous episodes of VT/VF did not differ between SP and PP
A B
Figure 6 A: Kaplan-Meier curves demonstrating freedom from inappropriate shocks between secondary and primary prevention subcutaneous implantable
deﬁbrillator patients. B: Kaplan-Meier curves demonstrating freedom from inappropriate shocks between primary prevention patients with an ejection fraction
≤35% (PP EF ≤35%) and with an ejection fraction435% (PP EF435%).
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of patients in all groups had a successfully converted induced
arrhythmia at the time of implantation. Likewise, conversion
of discrete spontaneous episodes of VT/VF was consistently
100%, and conversion upon ﬁrst shock was approximately
90% in each group. These ﬁndings are consistent with data
from large TV-ICD PP trials such as Sudden Cardiac Death
in Heart Failure Trial,4 which documented an 86% ﬁrst shock
conversion rate, and more recent broad inclusion studies of
both PP and SP patients, such as the Shockless IMPLant
Evaluation trial,17 where ﬁrst shock efﬁcacy was 89% in
the deﬁbrillation threshold testing arm and 92% in the
no–deﬁbrillation threshold testing arm.
Higher risk of inappropriate therapy has been documented
in younger patients18,19 and those with congenital arrhythmic
disorders20 and hypertrophic cardiomyopathies.21,22 In this
study of S-ICD patients, the incidence of inappropriate
therapy was not linked to indication or EF level. There were
no differences in overall rates seen between SP and PP
cohorts or within the PP subanalysis cohorts, even in the
younger high-risk PP EF 435% cohort. A clear impact of
device programming was, however, demonstrated with
patients programmed to a dual-zone conﬁguration, having
a substantially lower incidence of inappropriate therapy as
previously described.8,23Treatment of VT/VF and mortality
It is known that PP patients, in general, have a lower risk of
receiving an appropriate therapy than do SP patients.24,25
The present analysis demonstrates similar ﬁndings, with PP
patients overall experiencing lower numbers of VT/VFepisodes and being half as likely to receive an appropriate
therapy, despite a lower use of antiarrhythmic drugs (4.7% vs
21.2% in the IDE study). Since the S-ICD does not provide
antitachycardia pacing (ATP), the rates of treated vs
untreated VT/VF episodes are of particular interest. This
analysis is the ﬁrst to examine the incidence of VT/VF at an
episode level. It shows that as a result of the S-ICD detection
and treatment algorithms, there are substantial numbers of
episodes that are allowed to self-terminate, avoiding delivery
of unnecessary therapy. Interestingly, approximately half of
the appropriately sensed VT/VF episodes in the PP group
were self-terminating as compared with only 30% in the SP
group. Over the mean follow-up duration of 22 months,
9.8% of PP EF ≤35% patients had at least 1 episode of
VT/VF that was allowed to self-terminate, with no indication
of an associated increase in arrhythmic mortality.
The resulting incidence of delivered appropriate shock in
this cohort was 3.9% annually, similar to the incidence rate
of shock in the Multicenter Automatic Deﬁbrillator Implan-
tation Trial-Reduce Inappropriate Therapy trial26 despite its
use of ATP and modern programming (conventional pro-
gramming arm 4%; high rate programming arm 4%; delayed
therapy arm 3%), although not matched for etiologies.
The present study provides further insight into the low
mortality rates previously reported from these S-ICD studies,
given that the younger age and varied etiology have made
comparisons to other ICD studies difﬁcult. In the present
analysis, the overall mortality rate during follow-up was low (a
total of 26 deaths or 3.0% of the total population over a median
follow-up duration of 644 days), and despite the higher incidence
of appropriate therapy in the SP group, there was no indication of
an increased risk of death in that group. The highest mortality rate
Heart Rhythm, Vol 0, No 0, ] 20168(3.0% annual risk) was in fact documented within the PP EF
≤35% patient cohort, which is most likely related to the fact that
these patients were signiﬁcantly older and sicker than patients in
other cohorts. An important observation from our analysis of
mortality demonstrated that in the PP EF435% group no deaths
were reported during follow-up in 147 patients. With low
complications and high conversion rates, these data support
S-ICD use, particularly in these patients, and indeed this has been
a population commonly associated with the S-ICD. Even so, the
higher mortality rate of the older, sicker PP patients with an EF
≤35% was similar to that documented in the Multicenter
Automatic Deﬁbrillator Implantation Trial-Reduce Inappropriate
Therapy trial (annual Kaplan-Meier estimate per arm 5%, 2%,
and 4%)26. Further insight into mortality rates in these more
standard PP ICD patients can be gained from the Déﬁbrillateur
Automatique Implantable en Prévention Primaire registry,14
wherein the researchers reported PP outcomes by age: mortality
of 3.1% in patients aged 18–59 years (mean 51 years), 5.7% in
patients aged 60–74 years (mean 67.6 years), and 7.6% in
patients aged ≥74 years (mean 77.8 years). In our study, PP EF
≤35% patients implanted with an S-ICD had a mean age of 57
years and did well in comparison to a low annual mortality of
3.0%. The controlled pivotal studies of ICD therapy for PP show
a similar age affect, although slightly higher overall rates. A
recent meta-analysis27 of mortality rates from pivotal PP trials
reported that patients with a reduced EF and younger than 55
years died at a rate of 8.1% over 2.6 years of follow-up (3.2%
annually) and patients aged 55–64 years died at a rate of 18.4%
over 2.6 years (7.1% annually). Given these studies are not
matched for etiologies and other important factors, randomized
trials designed to study morbidity and mortality will be needed to
determine whether S-ICD use has a potential survival beneﬁt in
comparison to TV-ICD use.Study limitations
The retrospective nature of the data leads to certain
limitations in this analysis, and the differences in the
study design and follow-up between the US IDE study and
EFFORTLESS Registry are acknowledged. The patients
included in these S-ICD studies do not represent the total
ICD population because of S-ICD exclusion criteria and
other selection bias. Reduced vs preserved EF group
analyses do not include the 12% of PP patients with
missing EF measures, primarily comprising younger
patients with inherited diseases and fewer comorbidities,
which may limit the understanding of the preserved EF
cohort in this analysis. As expected, demographic char-
acteristics and medical history vary signiﬁcantly between
groups, including a signiﬁcantly higher percentage of SP
patients with a history of ICD device implantation than of
PP patients. Antiarrhythmic drug use was higher for SP in
the IDE study and unknown in the EFFORTLESS study,
and differences in the incidence of treated and untreated
VT/VF between groups may be caused, in part, by differ-
ences in antiarrhythmic drug use. Mortality comparisons
are limited because the mode of death was not available,nor was the mortality rate of patients withdrawn from the
study. Conclusions about TV-ICD comparisons discussed
are limited, as the overall patient population varies from
TV-ICD trials referenced, and it cannot be assumed that
longer-term outcomes will follow a similar trajectory as in
TV-ICD patients. Furthermore, longer follow-up beyond
the current 2 years is needed to understand long-term
beneﬁts and drawbacks of S-ICD therapy.
Conclusion
The S-ICD performs well in protecting both PP and SP
patients from sudden cardiac death, including PP patients
with EF values of435% or ≤35%. In the S-ICD implanted
population studied, there were no signiﬁcant differences in
device performance between groups relative to device- and
procedure-related complication rates, inappropriate shock
rates, or conversion efﬁcacy. Mortality rates were low and
well aligned with age and comorbidity differences observed
between the studied groups. In PP patients, the incidence of
VT/VF episodes was markedly lower than that in SP
patients, and episodes were more often self-terminating than
requiring a shock. This study supports S-ICD consideration
in SP patients without a history of bradycardia or ATP-
terminable monomorphic VT events and in all PP patients
not requiring pacing.
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